Abuse deterrent opioids

Turk, 1994, Physicians' attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain, Pain, 59, 201, 10.1016/0304-3959(94)90072-8 Manchikanti, 2006, Prescription drug abuse: What is being done to address this new drug epidemic?, Pain Physician, 9 Fleming, 2010, Tamper-resistant properties and bioavailability of a novel, multiparticulate, extended-release formulation of oxycodone for the treatment of moderate to severe pain, Pain Med, 11, 317 Friedmann N, Butera P, Klutzaritz D, et al: Abuse-resistant, longacting oxycodone treats chronic pain in a large phase III study: Presented at the 12Th World Congress on Pain, Glasgow, Scotland, 2008 (abstract) Parasrampuria, 2007, Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans, J Clin Pharmacol, 47, 1476, 10.1177/0091270007308615 Katz, 2008, Efficacy and safety evaluation of an extended-release morphine sulfate formulation with sequestered naltrexone for the treatment of osteoarthritis, J Pain, 9, 41, 10.1016/j.jpain.2008.01.181 Johnson F, Jones JB, Stauffer J: Relative bioavailability of naltrexone from crushed ALO-01 (an investigational, abuse-deterrent, extended-release morphine sulfate formulation with sequestered naltrexone hydrochloride) to a naltrexone oral solution, in Poster Presentation at American Pain Society's 27th Annual Scientific Meeting, abstract:236, 2008 Webster, 2006, Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain, J Pain, 7, 937, 10.1016/j.jpain.2006.05.005 Largent-Milnes, 2008, Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor Gs coupling, J Pain, 9, 700, 10.1016/j.jpain.2008.03.005